Antifungal Drugs Market, by Drug Type (Echinocandins, Polyenes, Allylamines, Azoles, and Others), by Indication (Aspergillosis, Dermatophytosis, Candidiasis, Mucormycosis, and Others), by Dosage Form (Powders, Ointments, Drugs, and Others), and by Region

Antifungal Drugs Market, by Drug Type (Echinocandins, Polyenes, Allylamines, Azoles, and Others), by Indication (Aspergillosis, Dermatophytosis, Candidiasis, Mucormycosis, and Others), by Dosage Form (Powders, Ointments, Drugs, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Antifungal drugs are used to treat fungal infections in individuals. Common fungal infections such as fungal nail infection, and ringworm etc. usually occur on the external surface of the body, while certain invasive fungal infections occur inside the body tissues or inside internal organs such as lungs and brain. Fungal infection is usually associated with individuals having weak immune system, such as people suffering from HIV/AIDS. Moreover, patients undergoing chemotherapy are susceptible to invasive fungal infections. Antifungal drugs act against the fungal infections by either killing the fungal cells or by inhibiting their growth. Antifungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.
Market Dynamics
Major players in the market are focused on growth strategies such as collaborations and agreements in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered into an agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution rights of Beasilea’s antifungal treatments. Pfizer will manufacture and distribute drugs for the treatment of life-threatening invasive mold infections in regions like Russia, Israel, Europe (excluding Nordics), and Turkey.
Similarly, key players in the market are focused on various business strategies such as research and development in order to expand their product portfolio. Increasing drug development is expected to drive growth of this market. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from their first interim efficiency analysis of an ongoing FURI study. The development of this novel treatment is indicated for antifungal treatment.
Key features of the study:
This report provides an in-depth analysis of global antifungal drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global antifungal drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global antifungal drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antifungal drugs market
Detailed Segmentation:
Global Antifungal Drugs Market, By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
Global Antifungal Drugs Market, By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
Global Antifungal Drugs Market, By Dosage Form:
Powders
Ointments
Drugs
Others
Global Antifungal Drugs Market, By Region:
North America
By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
By Dosage Form:
Powders
Ointments
Drugs
Others
By Country:
U.S.
Canada
Latin America
By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
By Dosage Form:
Powders
Ointments
Drugs
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
By Dosage Form:
Powders
Ointments
Drugs
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
By Dosage Form:
Powders
Ointments
Drugs
Others
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
By Dosage Form:
Powders
Ointments
Drugs
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Echinocandins
Polyenes
Allylamines
Azoles
Others
By Indication:
Aspergillosis
Dermatophytosis
Candidiasis
Mucormycosis
Others
By Dosage Form:
Powders
Ointments
Drugs
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
GlaxoSmithKline Plc *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bayer AG
Abbott Laboratories
Merck & Co., Inc
Glenmark Pharmaceuticals Limited
Enzon Pharmaceuticals, Inc.
Pfizer Inc.
Gilead Sciences, Inc.
Sanofi S.A.
Astellas Pharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.